Clinical Trial Update: Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide [Phase 2]

View source ↗

Summary

Phase 2 trial comparing aprepitant (Emend) plus ondansetron versus ondansetron alone to prevent chemotherapy-induced nausea and vomiting in glioma patients rece…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• EMEND (aprepitant)
• Zofran (Ondansetron)

Snippet

Sponsor: Katy Peters | Conditions: Nausea, Vomiting | Phase 2 | Status: COMPLETED | Results posted: 2018-06-26